Please assess the completion status of the following clinical trial:

Trial Title: Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males or non-pregnant/non-breast feeding females~* At least 30 years of age~* Diagnosis of idiopathic Parkinson''s disease (Hoehn \& Yahr criteria)~* Completed either Study 167 or Study 164~Exclusion Criteria:~* Presence of uncontrolled psychiatric, hematological, renal, hepatic,endocrinological, neurological, cardiovascular disease or active malignancy~* Dizziness or fainting due to orthostatic hypotension on standing~* Significant sleep disorder~* Drug abuse or alcoholism

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): Open label medication - Ropinirole CR

Based on this trial design, predict the completion outcome and termination type (if applicable).